You have read all your free articles, to continue reading subscribe to read the rest of this content.
Diamyd Medical announces that the first six-month interim report from DIAGNODE-1, a clinical pilot study in which the diabetes vaccine Diamyd is administered directly into lymph nodes, preliminarily shows that the treatment appears to be safe and tolerable and that the clinical progression in patienAlready a subscriber Login You have…
The company has announced new data from its Novel START trial, an open-label trial designed to reflect real-world practice. The results demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma, reports the company. TheAlready a subscriber Login You have read all your free articles,…
The first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer. The Phase I study is a dose escalation study in patients with advanced cancer and this is the first time ATOR-1017…
Swedish Orphan Biovitrum has announced that the first patient has been dosed in the phase 3, open-label, interventional XTEND-Kids study of efanesoctocog alfa (BIVV001) in paediatric subjects with severe haemophilia A. The XTEND-Kids study is designed to investigate the efficacy, safety and pharmAlready a subscriber Login You have read all…
